Y-mAbs Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Y-mAbs Therapeutics generated cash of -$27,232,000, which is more than the previous year. Cash used in financing activities reached the amount of $100,000 last year. Net change in cash is therefore -$27,125,000.
Cash Flow
| 2016 | -11.16M | 0 | 18.97M |
|---|---|---|---|
| 2017 | -15.87M | 0 | 89.58M |
| 2018 | -41.22M | -234K | 98.76M |
| 2019 | -73.49M | -1.96M | 134.70M |
| 2020 | -91.23M | -2.78M | 2.00M |
| 2021 | -102.55M | 61.04M | 108.31M |
| 2022 | -75.92M | 0 | 84K |
| 2023 | -27.23M | 0 | 100K |
YMAB Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 105.76M | 181.56M | 114.63M | 207.13M | 147.87M | 90.51M | 16.87M | 9.06M |
Operating activities | ||||||||
Net income | -21.42M | -95.56M | -55.27M | -119.33M | -81.02M | -43.27M | -19.16M | -17.05M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 735K | 839K | 782K | 396K | 166K | 29K | 0 | 0 |
Stock-based compensation expense | 14.45M | 25.60M | 19.33M | 16.13M | 4.65M | 0 | 609K | 258K |
| Deferred income tax benefit | 14.45M | 25.60M | 19.33M | 16.13M | 4.65M | 0 | 609K | 258K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -9.92M | -4.81M | -7.71M | -7.37M | 0 | 0 | 0 | 0 |
Inventories | 1.63M | -1.19M | -5.51M | 7.37M | 0 | 0 | 0 | 0 |
Accounts payable | -6.85M | -919K | 4.18M | 852K | 2.61M | 1.26M | 2.38M | 836K |
Cash generated by operating activities | -27.23M | -75.92M | -102.55M | -91.23M | -73.49M | -41.22M | -15.87M | -11.16M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -967K | -175K | -1.96M | -234K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 61.04M | -2.78M | -1.96M | -234K | 0 | 0 |
Financing activities | ||||||||
Common Stock Issued | 100K | 84K | 107.72M | 2.00M | 134.70M | 99.76M | 89.84M | 19.33M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -366K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 100K | 84K | 108.31M | 2.00M | 134.70M | 98.76M | 89.58M | 18.97M |
Net Change In Cash | -27.12M | -75.80M | 66.93M | -92.50M | 59.26M | 57.35M | 73.60M | 7.80M |
Cash at end of period | 78.63M | 105.76M | 181.56M | 114.63M | 207.13M | 147.87M | 90.48M | 16.87M |
| Data source | Data source | Data source | Data source | Data source | Data source |